Effect of cicletanine on overpacing-induced ST-segment elevation in conscious rabbits. A comparison with verapamil

Does mean arterial blood pressure scale with body mass in mammals? Effects of measurement of blood pressure

For at least the last 30 years, it has been discussed whether mean arterial blood pressure (MAP) is independent of body mass or whether it increases in accordance with the vertical height between the heart and the brain. The debate has centred on the most appropriate mathematical models for analysing allometric scaling and phylogenetic relationships; there has been previously little focus on evaluating the validity of underlying physiological data. Currently, the 2 most comprehensive scaling analyses are based on data from 47 species of mammals, based on 114 references. We reviewed all available references to determine under which physiological conditions MAP had been recorded. In 44 (38.6%) of the cited references, MAP was measured in anaesthetized animals. Data from conscious animals were reported in 59 (51.8%) of references; of these, 3 (2.6%) were radiotelemetric studies. In 5 species, data were reported from both anaesthetized and conscious animals, and the mean difference in the MAP between these settings was 20 ± 29 mm Hg. From a literature search, we identified MAP measurements performed by radiotelemetry in 11 of the 47 species included in the meta-analyses. A Bland-Altman analysis showed a bias of 1 mm Hg with 95% confidence interval (from -35 to 36 mm Hg); that is, the limits of agreement between radiotelemetric studies and studies in restrained animals were double the supposed difference in the MAP between the mouse and elephant. In conclusion, the existing literature does not provide evidence for either a positive or neutral scaling of arterial pressure to body mass across taxa.

Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine

We studied the effect of the furopyridine derivative antihypertensive drug, cicletanine, on blood pressure, vascular nitric oxide (NO) and cyclic guanosine 3':5'-monophosphate (cGMP) content in the aorta and the renal and carotid arteries, aortic superoxide production, and serum nitrotyrosine level in hypertensive/atherosclerotic rabbits. The effect of cicletanine was compared to that of furosemide. Rabbits were fed a normal or a cholesterol-enriched (1.5%) diet over 8 weeks. On the 8th week, the rabbits were treated per os with 2 x 50 mg/kg daily doses of cicletanine, furosemide, or vehicle for 5 days (n = 5-6 in each groups). The cholesterol diet increased mean arterial blood pressure (MABP) from 86 +/- 1 to 94 +/- 2 mm Hg (p < 0.05). Cicletanine decreased MABP in atherosclerotic rabbits to 85 +/- 1 mm Hg (p < 0.05), but it did not affect MABP in normal animals. Furosemide was without effect in both groups. In normal animals, NO content (assessed by electron spin resonance after in vivo spin trapping) in the aorta and the renal and carotid arteries was increased by cicletanine, and the drug increased cGMP in the renal artery as measured by radioimmunoassay. The cholesterol-enriched diet decreased both vascular NO and cGMP and increased aortic superoxide production assessed by lucigenin-enhanced chemiluminescence and serum nitrotyrosine determined by ELISA. In atherosclerotic animals, cicletanine increased NO and cGMP content in the aorta and the renal and carotid arteries and decreased aortic superoxide production and serum nitrotyrosine. Furosemide did not influence these parameters. We conclude that cicletanine lowers blood pressure in hypertensive/atherosclerotic rabbits. The antihypertensive effect of the drug in atherosclerosis may be based on its beneficial effects on the vascular NO-cGMP system and on the formation of reactive oxygen species.

The principle of laplace and scaling of ventricular wall stress and blood pressure in mammals and birds

Maximum left ventricular wall stress is calculated at end-diastolic volume and systemic arterial diastolic blood pressure, according to a thick-walled model for the principle of Laplace. Stress is independent of body mass and averages 13.9 kPa (+/-2.3; 95% confidence interval) in 24 species of mammals weighing 0.025-4,000 kg and 15.5 kPa (+/-4.7) in 12 birds weighing 0.014-110 kg. Birds have higher arterial blood pressures and larger hearts than mammals. Systolic and diastolic arterial blood pressures increase with body mass according to M(0.05) in mammals, and heart mass increases according to M(1.06) in the same species, further supporting the principle. However, blood pressure in birds is independent of body mass, and heart mass scales isometrically. End-diastolic stress values, calculated according to Laplace, are about one-third of peak stresses recorded in isolated mammalian myocardial preparations.

Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits

Myocardial ischemia assessed by intracavital ST-segment elevation, shortening of ventricular effective refractory period (VERP), and increase in left ventricular end-diastolic pressure (LVEDP) was provoked by ventricular overdrive pacing (VOP) in conscious rabbits. Cromakalim (10 micrograms/kg), an ATP-sensitive K+ channel opener, and cicletanine (30 mg/kg), a cGMP-phosphodiesterase inhibitor, reduced VOP-induced ST-segment elevation and LVEDP-increase. Under resting conditions, cromakalim lowered blood pressure, increased heart rate (HR), and shortened VERP, whereas cicletanine decreased HR, prolonged VERP without changing blood pressure. Co-administration of cromakalim and cicletanine additively reduced VOP-induced ST-segment elevation, shortening of VERP, and LVEDP-increase. Cicletanine did not change cromakalim-induced hypotension but abolished reflexogenic tachycardia. This suggests that VERP shortening is not a prerequisite for the anti-ischemic effect of cromakalim, and the combination of these drugs may afford a potent and safe anti-ischemic effect without affecting hypotension induced cromakalim.

Comparison of in vitro effects of cicletanine, its enantiomers and major metabolite on rat thoracic aorta

The effects of cicletanine ((+/-)-cic)), its optical isomers (BN-50417,(+)-cic); (BN-50418,(-)-cic) and major metabolite (BN-50699,cic-Met) on active tension were investigated in rat thoracic aortas. (+/-)-cic, (+)-cic, (-)-cic shifted the K(+)-concentration response curve to the right and depressed the maximum contractile response. Cic-Met was devoid of inhibitory effect on K(+)-induced contractions. (-)-Pinacidil had a far more potent inhibitory effect on K(+)-induced contractions than the cicletanine enantiomers and shifted the K(+)-concentration response curve to the right without affecting the maximum contractile response. (+/-)-Cic and nifedipine caused a concentration-related inhibition of Ca(2+)-induced contractions. Nifedipine was far more potent than (+/-)-cic in this respect. The slope of the Schild plot for nifedipine was not different from unity contrary to the significantly different slope for (+/-)-cic. (+/-)-Cic, (+)-cic, (-)-cic and cic-Met (3 x 10(-5) M to 3 x 10(-4) M) caused a concentration-related relaxation of noradrenaline (NA), serotonin (5-HT) and prostaglandin F2 alpha (PGF2 alpha)-induced contractions. In NA-precontracted preparations (-)-cic (10(-4) M-3 x 10(-4) M) had a stronger relaxant effect than (+)-cic. Cic-Met was a weaker antagonist of NA-induced contractions than (+) and (-)-cic. The enantiomers were far less potent relaxing NA-induced contractions than phentolamine. (+)-Cic, (-)-cic and cic-Met had a similar relaxant effect on 5-HT-induced contractions.(ABSTRACT TRUNCATED AT 250 WORDS)

Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits

In conscious rabbits equipped with right ventricular electrode and left ventricular polyethylene catheters, zaprinast and cicletanine, inhibitors of phosphodiesterase (PDE) V and PDEs I and V, respectively, as well as verapamil, a Ca2+ channel blocker, decreased intracavital ST-segment elevation induced by ventricular overdrive pacing (VOP). Zaprinast and cicletanine attenuated VOP-induced QT reduction and increase in left ventricular end-diastolic pressure (LVEDP), whereas verapamil increased LVEDP. These results suggest that inhibition of cGMP-PDEs can protect heart against ischemia.